Skip to content

Study · Animal study (in vivo) · mouse · 2006

14 results

Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.

Rockenstein E, Torrance M, Mante M, Adame A, Paulino A, Rose JB, Crews L, Moessler H, Masliah E

Journal of neuroscience research1 May 2006Cited by 61 (Europe PMC)

PMID16511867 (opens in a new tab)DOI10.1002/jnr.20818 (opens in a new tab)PepBankPUB-16511867
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In APP transgenic mice, Cerebrolysin reduced spatial learning deficits in the water maze.

    In plain wordsIn mice, Cerebrolysin reduced spatial learning deficits.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseSpatial learning deficits
    Study

    mousen: not reported in source

    APP transgenic mouse model
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 6 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Consistent with previous studies, Cerebrolysin ameliorated the performance deficits in the spatial learning portion of the water maze and reduced the synaptic pathology and amyloid burden in the brains of APP tg mice.
    1 context sentence
    Summary · context
    To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin
  2. 02AnimalAnimal study (in vivo)Mechanism

    In APP transgenic mice, Cerebrolysin reduced synaptic pathology.

    In plain wordsIn mice, Cerebrolysin reduced synaptic damage.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseSynaptic pathology
    Study

    mousen: not reported in source

    APP transgenic mouse model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 6 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Consistent with previous studies, Cerebrolysin ameliorated the performance deficits in the spatial learning portion of the water maze and reduced the synaptic pathology and amyloid burden in the brains of APP tg mice.
    1 context sentence
    Summary · context
    To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin
  3. 03AnimalAnimal study (in vivo)Mechanism

    In APP transgenic mice, Cerebrolysin reduced brain amyloid burden.

    In plain wordsIn mice, Cerebrolysin reduced brain amyloid deposits.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseAmyloid burden
    Study

    mousen: not reported in source

    APP transgenic mouse model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 6 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Consistent with previous studies, Cerebrolysin ameliorated the performance deficits in the spatial learning portion of the water maze and reduced the synaptic pathology and amyloid burden in the brains of APP tg mice.
    1 context sentence
    Summary · context
    To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin
  4. 04AnimalAnimal study (in vivo)Mechanism

    In APP transgenic mice, Cerebrolysin effects were associated with reduced full-length APP levels.

    In plain wordsIn mice, Cerebrolysin effects were linked to lower full-length APP levels.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseFull-length APP levels
    Study

    mousen: not reported in source

    APP transgenic mouse model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 6 monthsAs given in this study (mouse).

    Source sentences

    Summary
    These effects were associated with reduced levels of FL APP and APP C-terminal fragments, but levels of BACE1, Notch1, Nep, and IDE were unchanged.
    1 context sentence
    Summary · context
    To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin
  5. 05AnimalAnimal study (in vivo)Mechanism

    In APP transgenic mice, Cerebrolysin effects were associated with reduced APP C-terminal fragment levels.

    In plain wordsIn mice, Cerebrolysin effects were linked to lower APP fragment levels.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseAPP C-terminal fragment levels
    Study

    mousen: not reported in source

    APP transgenic mouse model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 6 monthsAs given in this study (mouse).

    Source sentences

    Summary
    These effects were associated with reduced levels of FL APP and APP C-terminal fragments, but levels of BACE1, Notch1, Nep, and IDE were unchanged.
    1 context sentence
    Summary · context
    To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin
  6. 06AnimalAnimal study (in vivo)Mechanism

    In APP transgenic mice, BACE1 levels were unchanged with Cerebrolysin.

    In plain wordsIn mice, BACE1 levels did not change with Cerebrolysin.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeBACE1 levels
    Study

    mousen: not reported in source

    APP transgenic mouse model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 6 monthsAs given in this study (mouse).

    Source sentences

    Summary
    These effects were associated with reduced levels of FL APP and APP C-terminal fragments, but levels of BACE1, Notch1, Nep, and IDE were unchanged.
    1 context sentence
    Summary · context
    To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin
  7. 07AnimalAnimal study (in vivo)Mechanism

    In APP transgenic mice, Notch1 levels were unchanged with Cerebrolysin.

    In plain wordsIn mice, Notch1 levels did not change with Cerebrolysin.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeNotch1 levels
    Study

    mousen: not reported in source

    APP transgenic mouse model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 6 monthsAs given in this study (mouse).

    Source sentences

    Summary
    These effects were associated with reduced levels of FL APP and APP C-terminal fragments, but levels of BACE1, Notch1, Nep, and IDE were unchanged.
    1 context sentence
    Summary · context
    To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin
  8. 08AnimalAnimal study (in vivo)Mechanism

    In APP transgenic mice, neprilysin levels were unchanged with Cerebrolysin.

    In plain wordsIn mice, neprilysin levels did not change with Cerebrolysin.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeNeprilysin levels
    Study

    mousen: not reported in source

    APP transgenic mouse model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 6 monthsAs given in this study (mouse).

    Source sentences

    Summary
    These effects were associated with reduced levels of FL APP and APP C-terminal fragments, but levels of BACE1, Notch1, Nep, and IDE were unchanged.
    1 context sentence
    Summary · context
    To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin
  9. 09AnimalAnimal study (in vivo)Mechanism

    In APP transgenic mice, insulin-degrading enzyme levels were unchanged with Cerebrolysin.

    In plain wordsIn mice, insulin-degrading enzyme levels did not change with Cerebrolysin.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeInsulin-degrading enzyme levels
    Study

    mousen: not reported in source

    APP transgenic mouse model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 6 monthsAs given in this study (mouse).

    Source sentences

    Summary
    These effects were associated with reduced levels of FL APP and APP C-terminal fragments, but levels of BACE1, Notch1, Nep, and IDE were unchanged.
    1 context sentence
    Summary · context
    To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin
  10. 10AnimalAnimal study (in vivo)Mechanism

    In APP transgenic mice, Cerebrolysin reduced active CDK5 levels.

    In plain wordsIn mice, Cerebrolysin reduced active CDK5 levels.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseActive CDK5 levels
    Study

    mousen: not reported in source

    APP transgenic mouse model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 6 monthsAs given in this study (mouse).

    Source sentences

    Summary
    In contrast, levels of active cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3beta [GSK-3beta; but not stress-activated protein kinase-1 (SAPK1)], kinases that phosphorylate APP, were reduced.
    1 context sentence
    Summary · context
    To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin
  11. 11AnimalAnimal study (in vivo)Mechanism

    In APP transgenic mice, Cerebrolysin reduced active GSK-3beta levels.

    In plain wordsIn mice, Cerebrolysin reduced active GSK-3beta levels.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseActive GSK-3beta levels
    Study

    mousen: not reported in source

    APP transgenic mouse model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 6 monthsAs given in this study (mouse).

    Source sentences

    Summary
    In contrast, levels of active cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3beta [GSK-3beta; but not stress-activated protein kinase-1 (SAPK1)], kinases that phosphorylate APP, were reduced.
    1 context sentence
    Summary · context
    To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin
  12. 12AnimalAnimal study (in vivo)Mechanism

    In APP transgenic mice, Cerebrolysin did not reduce SAPK1 levels.

    In plain wordsIn mice, Cerebrolysin did not reduce SAPK1 levels.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeSAPK1 levels
    Study

    mousen: not reported in source

    APP transgenic mouse model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 6 monthsAs given in this study (mouse).

    Source sentences

    Summary
    In contrast, levels of active cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3beta [GSK-3beta; but not stress-activated protein kinase-1 (SAPK1)], kinases that phosphorylate APP, were reduced.
    1 context sentence
    Summary · context
    To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin
  13. 13AnimalAnimal study (in vivo)Mechanism

    In APP transgenic mice, Cerebrolysin reduced phosphorylated APP levels.

    In plain wordsIn mice, Cerebrolysin reduced phosphorylated APP levels.

    Peptide
    Cerebrolysin
    Outcome
    DecreasePhosphorylated APP levels
    Study

    mousen: not reported in source

    APP transgenic mouse model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 6 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, Cerebrolysin reduced the levels of phosphorylated APP and the accumulation of APP in the neuritic processes.
    1 context sentence
    Summary · context
    To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin
  14. 14AnimalAnimal study (in vivo)Mechanism

    In APP transgenic mice, Cerebrolysin reduced APP accumulation in neuritic processes.

    In plain wordsIn mice, Cerebrolysin reduced APP accumulation in nerve-cell processes.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNeuritic APP accumulation
    Study

    mousen: not reported in source

    APP transgenic mouse model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 6 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, Cerebrolysin reduced the levels of phosphorylated APP and the accumulation of APP in the neuritic processes.
    1 context sentence
    Summary · context
    To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.